Author： DiSantostefano Rachael L. Biddle Andrea K.
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.24, Iss.2, 2006-01, pp. : 171-191
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Treatment options for benign prostatic hyperplasia
By Thurlow R.J.
Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. :
Access to resources
Recommend
Dutasteride for the treatment of benign prostatic hyperplasia
Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. :
Dutasteride/Tamsulosin: In Benign Prostatic Hyperplasia
Drugs & Aging, Vol. 29, Iss. 5, 2012-05 ,pp. :
By Warren Emma Pollicino Christine Curtis Bradley Evans Wendell Sbaraini Alexandra Schwarz Eli
Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. :
The mechanism of epristeride against benign prostatic hyperplasia
By Sun Z.-Y. Wu H.-Y. Wang M.-Y. Tu Z.-H.
European Journal of Pharmacology, Vol. 371, Iss. 2, 1999-04 ,pp. :